Efficacy and safety of aprotinin in aortocoronary bypass and valve replacement operations: A placebo-controlled randomized double-blind study

Perfusion

Volumn 11, Issue 4, 1996, Pages 313-318

  Rodrigus, I E ^a   Vermeyen, K M ^a   De Hert, S G ^a   Amsel, B J ^a   Walter, P J ^a  

^a ANTWERP UNIVERSITY HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFIBRINOLYTIC AGENT; APROTININ; KALLIKREIN;

ADULT; AGED; ARTICLE; BLOOD TRANSFUSION; CARDIOPULMONARY BYPASS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; DOUBLE BLIND PROCEDURE; DRUG COST; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEART VALVE REPLACEMENT; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; POSTOPERATIVE HEMORRHAGE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THORAX DRAINAGE; TIME;

EID: 0029777537     PISSN: 02676591     EISSN: None     Source Type: Journal    
DOI: 10.1177/026765919601100403     Document Type: Article

References (22)

1. Fritz H, Wunderer G. Biochemistry and applications of aprotinin, the kallikrein inhibitor from bovine organs. Arzneim-Forsch Drug Res 1983; 33: 479-94.
2. Royston D, Bidstrup BP, Taylor KM, Sapsford SN. Effect of aprotinin on the need for blood transfusion after repeat open heart surgery. Lancet 1987; ii: 1289-91.
3. van Oeveren W, Jansen NJ, Bidstrup BP et al. Effects of aprotinin on hemostatic mechanisms during cardiopulmonary bypass. Ann Thorac Surg 1987; 44: 640-45.
4. Harker LA, Malpass TW, Branson HE, Hessel EA, Slichter SJ. Mechanism of abnormal bleeding in patients undergoing cardiopulmonary bypass: acquired transient platelet dysfunction associated with selective alpha-granule release. Blood 1980; 56: 824-34.
5. Kaplan AP, Silverberg M. The coagulation-kinin pathway of human plasma. Blood 1987; 70: 1-5.
6. Havert J, Nicoloso G, Schleuning WD, Bachmann F, Schapira M. Plasminogen activators in dextran sulfate-activated euglobulin fractions: a molecular analysis of factor XII and prekallikrein dependent fibrinolysis. Blood 1989; 73: 994-99.
7. van Oeveren W, Eijsman L, Roozendaal KJ, Wildevuur CRH. Platelet preservation by aprotinin during cardiopulmonary bypass. Lancet 1988; i: 644.
8. Huiming Huang, Wenxiang Ding, Zhaohang Su, Weizhnong Zhang. Mechanism of the preserving effect of aprotinin on platelet function and its use in cardiac surgery. J Thorac Cardiovasc Surg 1993; 106: 11-18.
9. Royston D. High-dose aprotinin therapy: a review of the first five years' experience. J Cardiothorac Vasc Anesth 1992; 6: 76-100.
10. Bidstrup BP, Royston D, Taylor KM, Sapsford RN. Reduction in blood loss and blood use after cardiopulmonary bypass with high dose aprotinin (Trasylol). J Thorac Cardiovasc Surg 1989; 97: 364-72.
11. Friedrich G, Weber C, Bernard C, Hettwer A, Schlosser V. Reduction of blood transfusion requirement in open heart surgery by administration of high doses of aprotinin - preliminary results. Thorac Cardiovasc Surg 1989; 37: 89-91.
12. Dietrich W, Baranhay A, Dilthey G et al. Reduction of homologous blood requirement in cardiac surgery by intraoperative aprotinin application - clinical experience in 152 cardiac surgical patients. Thorac Cardiovasc Surg 1989; 37: 92-98.
13. Alajmo F, Calamai G, Perna AM et al. High dose aprotinin: hemostatic effects in open-heart operations. Ann Thorac Surg 1989; 48: 536-39.
14. van Oeveren W, Harder MP, Roozendaal KJ, Eijsman L, Wildevuur CRH. Aprotinin protects platelets against the initial effect of cardiopulmonary bypass. J Thorac Cardiovasc Surg 1990; 99: 788-97.
15. Royston D, Bidstrup BP, Taylor KM, Sapsford RN. Aprotinin reduces bleeding after open heart surgery in patients taking aspirin and those with renal failure. Anesthesiology 1989; 71: A6.
16. Bidstrup BP, Royston D, McGuiness C, Sapsford RN. Aprotinin in aspirin-pretreated patients. Perfusion 1990; 5(suppl): 77-81.
17. Murkin JM, Lux J, Shannon NA et al. Aprotinin significantly decreases bleeding and transfusion requirements in patients receiving aspirin and undergoing cardiac operations. J Thorac Cardiovasc Surg 1994; 107: 554-61.
18. Cosgrove DM. Use of aprotinin in repeat myocardial revascularization: Cleveland Clinic experience. Perfusion 1993; 8(suppl): 36-42.
19. Lemmer JH, Stanford W, Bonney SL et al. Aprotinin for coronary bypass operations: efficacy, safety, and influence on early saphenous vein graft patency. J Thorac Cardiovasc Surg 1994; 107: 543-53.
20. Freeman JG, Turner GA, Venables CW, Latner AL. Serial use of aprotinin and incidence of allergic reactions. Curr Med Res Opin 1983; 8: 559-61.
21. Royston D, Bidstrup BP, Sapsford RN, Taylor KM. Reduced blood loss after open heart surgery with aprotinin is associated with an increase in the activated clotting time. J Cardiothorac Anesth 1989; 3 (5, suppl 1): 80.
22. Baele PL, Ruiz-Gomez J, Londot C, Sauvage M, Van Dijck MJ, Robert A. Systematic use of aprotinin in cardiac surgery: influence on total homologous exposure and hospital cost. Acta Anaesth Belg 1992; 43: 103-12.